Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
76.43
+0.93 (1.23%)
Aug 12, 2026, 10:04 AM EDT - Market open
Nektar Therapeutics Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Nektar Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $153.22. The average 1-year stock price forecast is 100.47% higher than the current stock price, while the lowest is $80 (+4.67%) and the highest is $192 (+151.21%).
Price Target: $153.22 (+100.47%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Nektar Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 8 | 9 | 9 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $153 | Buy | Maintains | $153 | +100.18% | Aug 6, 2026 |
| Citi | Citi | Buy Maintains $151 | Buy | Maintains | $151 | +97.57% | Jul 21, 2026 |
| BTIG | BTIG | Buy Reiterates $178 | Buy | Reiterates | $178 | +132.89% | Jul 14, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $185 | Buy | Reiterates | $185 | +142.05% | Jul 1, 2026 |
| Wedbush | Wedbush | Hold Maintains $95 → $80 | Hold | Maintains | $95 → $80 | +4.67% | May 11, 2026 |
Financial Forecast
Revenue This Year
41.44M
from 55.23M
Decreased by -24.96%
Revenue Next Year
36.99M
from 41.44M
Decreased by -10.75%
EPS This Year
-9.54
from -8.66
EPS Next Year
-11.87
from -9.54
EPS and Forward PE are based on non-GAAP adjusted numbers.